376 related articles for article (PubMed ID: 23525624)
1. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T
Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413
[TBL] [Abstract][Full Text] [Related]
5. The oncolytic herpes simplex virus vector G47∆ effectively targets breast cancer stem cells.
Zeng W; Hu P; Wu J; Wang J; Li J; Lei L; Liu R
Oncol Rep; 2013 Mar; 29(3):1108-14. PubMed ID: 23292314
[TBL] [Abstract][Full Text] [Related]
6. Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.
Bourgeois-Daigneault MC; St-Germain LE; Roy DG; Pelin A; Aitken AS; Arulanandam R; Falls T; Garcia V; Diallo JS; Bell JC
Breast Cancer Res; 2016 Aug; 18(1):83. PubMed ID: 27503504
[TBL] [Abstract][Full Text] [Related]
7. Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus.
Wang JN; Xu LH; Zeng WG; Hu P; Rabkin SD; Liu RR
Asian Pac J Cancer Prev; 2015; 16(3):1241-5. PubMed ID: 25735362
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
Tan G; Kasuya H; Sahin TT; Yamamura K; Wu Z; Koide Y; Hotta Y; Shikano T; Yamada S; Kanzaki A; Fujii T; Sugimoto H; Nomoto S; Nishikawa Y; Tanaka M; Tsurumaru N; Kuwahara T; Fukuda S; Ichinose T; Kikumori T; Takeda S; Nakao A; Kodera Y
Int J Cancer; 2015 Apr; 136(7):1718-30. PubMed ID: 25156870
[TBL] [Abstract][Full Text] [Related]
9. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.
Passer BJ; Cheema T; Wu S; Wu CL; Rabkin SD; Martuza RL
Cancer Gene Ther; 2013 Jan; 20(1):17-24. PubMed ID: 23138870
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer.
Liu RB; Rabkin SD
Chin Med J (Engl); 2005 Feb; 118(4):307-12. PubMed ID: 15740669
[TBL] [Abstract][Full Text] [Related]
12. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models.
Shimoyama S; Goshima F; Teshigahara O; Kasuya H; Kodera Y; Nakao A; Nishiyama Y
Hepatogastroenterology; 2007 Jun; 54(76):1038-42. PubMed ID: 17629034
[TBL] [Abstract][Full Text] [Related]
13. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
Deguchi T; Shikano T; Kasuya H; Nawa A; Fujiwara S; Takeda S; Gewen T; Sahin TT; Yamada S; Kanzaki A; Yamamura K; Fujii T; Sugimoto H; Nomoto S; Fukuda S; Nishikawa Y; Kodera Y; Nakao A
Hepatogastroenterology; 2012 Sep; 59(118):1844-50. PubMed ID: 22172413
[TBL] [Abstract][Full Text] [Related]
14. The oncolytic herpes simplex virus vector, G47Δ, effectively targets tamoxifen-resistant breast cancer cells.
Fan J; Jiang H; Cheng L; Liu R
Oncol Rep; 2016 Mar; 35(3):1741-9. PubMed ID: 26718317
[TBL] [Abstract][Full Text] [Related]
15. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
17. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Liao Y; Zou YY; Xia WY; Hung MC
Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
[TBL] [Abstract][Full Text] [Related]
18. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
Hoffmann D; Bangen JM; Bayer W; Wildner O
Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
[TBL] [Abstract][Full Text] [Related]
19. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
20. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
Dong X; Qu W; Ma S; Zhu Z; Zheng C; He A; Karlsson A; Xu K; Zheng X
Cancer Lett; 2013 Jan; 328(1):95-103. PubMed ID: 23000515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]